Status:

COMPLETED

The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial

Lead Sponsor:

Bayside Health

Collaborating Sponsors:

National Health and Medical Research Council, Australia

Conditions:

Coronary Artery Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

To investigate the safety of nitrous oxide (N2O) anaesthesia in patients with risk factors for coronary artery disease undergoing major surgery.

Detailed Description

Approximately 25% of patients undergoing major surgery have known coronary artery disease (CAD) or risk factors for CAD. N2O interferes with vitamin B12 and folate metabolism. This impairs production...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Adult males and females age ≥ 45 years, undergoing noncardiac surgery and general anaesthesia expected to exceed two hours.
  • At increased risk of cardiac events, defined as any of
  • history of coronary artery disease as defined by a history of any one of the following: i. angina ii. MI iii. segmental wall motion abnormality on echocardiography or a fixed defect on radionuclide imaging iv. a positive exercise stress test for cardiac ischaemia v. a positive radionuclide exercise, echocardiographic exercise, or pharmacological cardiovascular stress test for cardiac ischaemia vi. coronary revascularization (CABG or PTCA) vii. angiographic evidence of atherosclerotic stenosis \> 50% of the diameter of any coronary artery viii. ECG with pathological Q waves in two contiguous leads
  • heart failure
  • cerebrovascular disease thought due to atherothrombotic disease
  • aortic or peripheral vascular disease
  • or three or more of the following risk factors:
  • age ≥70 years
  • any history of congestive heart failure
  • diabetes and currently on an oral hypoglycaemic agent or insulin therapy
  • current treatment for hypertension
  • preoperative serum creatinine \>175 micro mol/L (\> 2.0 mg/dl)
  • current or previous high cholesterol ≥6.2 mmol/L (\> 240 mg/dl)
  • history of a transient ischemic attack (TIA) (i.e. a transient focal neurological deficit that lasted less than 24 hours and thought to be vascular in origin)
  • emergency/urgent surgery (i.e. surgery which must be undertaken within 24 hours of acute presentation to hospital)
  • high-risk type of surgery (i.e. intrathoracic or intraperitoneal)
  • Exclusion Criteria
  • having cardiac surgery
  • marked impairment of gas-exchange expected to require Fi02\> 0.5 intraoperatively
  • specific circumstances where N2O is contraindicated (eg. volvulus, pulmonary hypertension, raised intracranial pressure) or the anaesthetist plans to use supplemental oxygen (eg. colorectal surgery)
  • N2O unavailable for use.

Exclusion

    Key Trial Info

    Start Date :

    April 1 2007

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    September 1 2013

    Estimated Enrollment :

    7112 Patients enrolled

    Trial Details

    Trial ID

    NCT00430989

    Start Date

    April 1 2007

    End Date

    September 1 2013

    Last Update

    December 4 2019

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Alfred Hosptial

    Melbourne, Victoria, Australia, 3004